SynthesisRheumatology international2025
Classic lipid profile and lipoprotein(a) in systemic sclerosis: a systematic review and meta-analysis of case-control studies.
Synthesis in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarker patterns across skin-lung-gut burden in systemic sclerosis.Frontiers in immunology · 2026Article
- Association of lipid parameters with the development of disease complications in patients with limited cutaneous systemic sclerosis: a prospective exploratory cohort study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsSystemic sclerosis (SSc) is a systemic autoimmune disease characterized by fibrosis, vascular abnormalities, and immune dysfunction. Whether patients with SSc exhibit lipid profile abnormalities, which may increase cardiovascular risk, remains uncertain. Our aim was to systematically investigate whether total cholesterol (TCHOL), triglycerides (TRG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and Lipoprotein (a) [Lp(a)] are affected in SSc patients.
methodsPubMed and Cochrane library databases were systematically searched up to 30 November 2024 for studies reporting on lipid profile (TCHOL, TRG, HDL-C, LDL-C) and Lp(a) in patients with SSc. Qualitative and quantitative syntheses of data from published prospective and retrospective studies was performed.
resultsLiterature search identified 27 eligible trials including 2503 participants, of whom 1114 were SSc patients and 1389 were healthy controls (HC). The pooled analysis from 24 studies (1001 SSc patients and 1254 HC) demonstrated that SSc patients had significantly lower HDL-C levels compared with the HC group (MD:- 5.61 mg/dl, 95% CI- 8.22,- 3.00, I
conclusionsHDL-C levels are decreased in SSc, contrary to TRG and Lp(a) levels, which are increased. These findings may have implications in assessing cardiovascular risk in patients with SSc. TRAIL REGISTRY: CRD42024607564.
Indexed as
Identifiers
40762859What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.